Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Inks Pact With Amplimmune
by Lisa M. Jarvis
August 9, 2010
| A version of this story appeared in
Volume 88, Issue 32
GlaxoSmithKline will pay up to $508 million for access to Amplimmune’s protein fusion therapies that target PD-1, a protein involved in regulating T-cell-mediated immune responses. Rockville, Md.-based Amplimmune scores $23 million up front and is eligible for milestones as its lead candidate, AMP-224, progresses in clinical trials. Amplimmune expects to file an Investigational New Drug Application with FDA and start a Phase I clinical trial of AMP-224 for treatment of cancer in 2011.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter